System1 Biosciences Revenue and Competitors



Total Funding



Estimated Revenue & Valuation

  • System1 Biosciences's estimated annual revenue is currently $2.6M per year.(i)
  • System1 Biosciences's estimated revenue per employee is $77,500
  • System1 Biosciences's total funding is $25M.

Employee Data

  • System1 Biosciences has 33 Employees.(i)
  • System1 Biosciences grew their employee count by -33% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
Add Company

System1 Biosciences, Inc., is a San Francisco based neurotherapeutics company that employs AI-driven phenotypic screening to discover novel drugs for complex neurological and psychiatric diseases such as epilepsy, autism, and schizophrenia, disorders for which current discovery techniques have proved least successful. System1 combines cerebral organoid science, systems neuroscience, robotic automation, and advanced data analytics to discover characterizations of disease never before achievable. These "deep phenotypes"​ are exploited to identify novel therapeutic targets and drug treatments.



Total Funding


Number of Employees


Revenue (est)


Employee Growth %





System1 Biosciences News

2022-04-20 - A novel cocktail therapy based on quintuplet combination of ...

... to activate the anti-tumor innate and adaptive immune system [1, 2]. ... real-time cell analyzer (ACEA Biosciences, U. S.) as reported.

2022-04-17 - Global Human Organoids Market Executive Summary and ...

System1 Biosciences (US); Cyfuse Biomedical (Japan). Regions & countries mentioned in report: North America (United States, Canada and Mexico)...

2022-04-06 - Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

System1 (NYSE:SST) shares are surging more than 14% as it continues ... Arcus Biosciences (NYSE:RCUS) stock is increasing more than 13% as...

2018-09-13 - System1 Biosciences raises $25M in Series A round for neurotherapeutics discovery platform

The company plans to use the money to fund its drug-discovery programs, which are focused on epilepsy, autism and schizophrenia. System1’s platform involves of using stem cell lines from patients with brain diseases to create cerebral organoids, described as three-dimensional in vitro systems a ...

2018-09-12 - System1 Raises $25M in Series A Funding

System1 Biosciences, Inc., a San Francisco, CA-based neurotherapeutics company that employs phenotypic screening to discover novel drugs for neurological and psychiatric disorders, completed a $25m Series A financing. The round was co-led by CRV and Pfizer Ventures with participation from Alexa ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding